Janux Therapeutics, Inc. (JANX)
Automate Your Wheel Strategy on JANX
With Tiblio's Option Bot, you can configure your own wheel strategy including JANX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol JANX
- Rev/Share 0.024
- Book/Share 15.7449
- PB 2.1588
- Debt/Equity 0.0232
- CurrentRatio 35.8624
- ROIC -0.1444
- MktCap 2044388033.0
- FreeCF/Share -1.1511
- PFCF -28.6341
- PE -20.6898
- Debt/Assets 0.0221
- DivYield 0
- ROE -0.1018
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | JANX | Wolfe Research | -- | Peer Perform | -- | -- | Nov. 18, 2025 |
| Initiation | JANX | Barclays | -- | Overweight | -- | $47 | Sept. 17, 2025 |
| Initiation | JANX | Stifel | -- | Buy | -- | $45 | Sept. 10, 2025 |
| Initiation | JANX | Truist | -- | Buy | -- | $100 | Sept. 10, 2025 |
| Initiation | JANX | Guggenheim | -- | Buy | -- | $72 | Sept. 4, 2025 |
| Initiation | JANX | Piper Sandler | -- | Overweight | -- | $42 | Aug. 19, 2025 |
| Initiation | JANX | Raymond James | -- | Outperform | -- | $65 | July 11, 2025 |
| Reiterated | JANX | BTIG Research | -- | Buy | $82 | $100 | Dec. 3, 2024 |
| Reiterated | JANX | H.C. Wainwright | -- | Buy | $63 | $70 | Dec. 3, 2024 |
| Initiation | JANX | Stifel | -- | Buy | -- | $70 | Sept. 6, 2024 |
News
Janux Therapeutics Stock Hits 52-Week Low After Trial Update
Published: December 02, 2025 by: Benzinga
Sentiment: Negative
Janux Therapeutics Inc. (NASDAQ: JANX) stock hit a 52-week low on Tuesday after the company released updated interim data for its JANX007 Phase 1 program for metastatic castration-resistant prostate cancer (mCRPC).
Read More
Janux Therapeutics (JANX) Moves 8.8% Higher: Will This Strength Last?
Published: October 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Janux Therapeutics (JANX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Read More
Janux Therapeutics (JANX) Surges 6.8%: Is This an Indication of Further Gains?
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Janux Therapeutics (JANX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Read More
About Janux Therapeutics, Inc. (JANX)
- IPO Date 2021-06-11
- Website https://www.januxrx.com
- Industry Biotechnology
- CEO David Alan Campbell
- Employees 91